Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
A new phase 3 clinical trial is testing sonrotoclax, a new BCL2 inhibitor, in combination with zanubrutinib for CLL.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
Great progress has been made in how we manage chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), so much so that patients may now have a normal life expectancy. But there is still much left to do.
December 2023 CLL Bloodline – Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
National Family Caregivers Month Quotes on Being a Care Partner to a Loved One With Chronic Lymphocytic Leukemia November is National Family Caregivers Month, and we are honoring all the vital
Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.
This new research identifies some of the genetic changes that drive the evolution of CLL to Richter’s syndrome.
Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).
Some see CLL / SLL as a solved problem. But unfortunately, we know better. This abstract from the European Hematology Association (EHA) Annual Congress in 2022 reinforced one of our greatest unsolved problems: what happens following treatment with a covalent BTK and BCL2 inhibitor.
One click to our most popular content.
